Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
Gli inibitori del recettore IIb/IIIa - Cuorediverona.it Gli inibitori del recettore IIb/IIIa - Cuorediverona.it
IIb/IIIa e PCI: Nei pazienti stabili
ISAR-REACT: 30 Day Endpoints 6 Death/MI/Urgent TVR (%) P=.82 6 Death (%) P=NS 6 Urgent TVR (%) P=NS 4 4.2 4.0 4 4 2 2 2 0.3 0.3 0.9 0.7 0 Abciximab Placebo 0 Abciximab Placebo 0 Abciximab Placebo
- Page 15 and 16: Patogenesi delle Sindromi Coronaric
- Page 17 and 18: Sindromi Coronariche Acute ST-segme
- Page 19: 8 16 Lancet 1997; 349:1429-35 35
- Page 22 and 23: UA/NSTEMI Beneficio solo se PCI
- Page 24 and 25: % of Patients IIb/IIIa Inhibition w
- Page 26 and 27: GP IIb/IIIa Inhibitor During Medica
- Page 28 and 29: Peterson E.D.et al.: Early use of g
- Page 30 and 31: ISAR-COOL study - Pre-procedural ou
- Page 32 and 33: CAPTURE Results by Troponin T Statu
- Page 34 and 35: GP IIb/IIIa Inhibition in Diabetics
- Page 36 and 37: Gli inibitori GP IIb/IIIa IIIa ridu
- Page 38 and 39: ESC PCI guidelines 2004 2004 Recomm
- Page 40 and 41: SCA: UA/NSTEMI L’applicazione del
- Page 42 and 43: Coronarografia in base a età e TIM
- Page 44 and 45: Sindromi Coronariche Acute ST-segme
- Page 46 and 47: Occlusive thrombus contains Fibrin
- Page 48 and 49: Abciximab Improves ST Res-90 min ST
- Page 50 and 51: RAPPORT, ISAR 2, ADMIRAL, CADILLAC
- Page 52 and 53: 5 GPIIb/IIIa inhibitors trials in P
- Page 54 and 55: BMS and abciximab display a synergi
- Page 56 and 57: Study design Inclusion Criteria: ST
- Page 58 and 59: Multi-STRATEGY MULTIcenter evaluati
- Page 60 and 61: GUSTO V AMI GUSTO V - Trial Schemat
- Page 62 and 63: IIb/IIIa Varie...ed eventuali
- Page 66: Conclusioni Glycoprotein IIb/IIIa I
ISAR-REACT: 30 Day Endpoints<br />
6<br />
Death/MI/Urgent TVR (%)<br />
P=.82<br />
6<br />
Death (%)<br />
P=NS<br />
6<br />
Urgent TVR (%)<br />
P=NS<br />
4<br />
4.2<br />
4.0<br />
4<br />
4<br />
2<br />
2<br />
2<br />
0.3 0.3<br />
0.9<br />
0.7<br />
0<br />
Abciximab<br />
Placebo<br />
0<br />
Abciximab<br />
Placebo<br />
0<br />
Abciximab<br />
Placebo
Change language